Immunome (IMNM)
(Delayed Data from NSDQ)
$10.46 USD
-0.39 (-3.59%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $10.46 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMNM 10.46 -0.39(-3.59%)
Will IMNM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMNM
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
IMNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Other News for IMNM
Immunome reports Q2 EPS (50c), consensus (50c)
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update | IMNM ...
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | IMNM Stock News
Bullish Two Hundred Day Moving Average Cross - IMNM
September 19th Options Now Available For Immunome (IMNM)